Vanguard Asset Management
LENZ

Vanguard Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Vanguard Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,103
Closed -$55.8K – 2487
2026
Q1 		$55.8K Buy
+6,103
New +$85.7K ﹤0.01% 2424

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Asset Management's LENZ Position: Q2 2026 in Review

Vanguard Asset Management sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 6,103 shares — an estimated $55.8K sold.

Vanguard Asset Management first reported a position in LENZ in Q1 2026 and held it in 1 quarter. The position peaked at $55.8K in Q1 2026. 129 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Vanguard Asset Management reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Asset Management sold 6,103 LENZ Therapeutics shares in Q2 2026, an estimated $55.8K.
  • Vanguard Asset Management first reported a position in LENZ Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Asset Management's LENZ Therapeutics position peaked at $55.8K in Q1 2026.
  • 129 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.